Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total value of $692,080.00. Following the completion of the transaction, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,472,066.41. This trade represents a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Andrew Guggenhime also recently made the following trade(s):

• On Wednesday, December 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $88.78, for a total transaction of $710,240.00.

Vaxcyte Price Performance

Vaxcyte stock opened at $89.97 on Friday. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The company has a market capitalization of $11.21 billion, a price-to-earnings ratio of -19.56 and a beta of 0.98. The firm’s fifty day moving average price is $87.29 and its 200 day moving average price is $93.88.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the previous year, the business earned ($0.91) EPS. Analysts forecast that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vaxcyte

Institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC raised its holdings in Vaxcyte by 23.1% in the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock valued at $1,247,954,000 after acquiring an additional 2,052,989 shares in the last quarter. RA Capital Management L.P. raised its stake in shares of Vaxcyte by 5.9% in the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock valued at $992,914,000 after purchasing an additional 485,436 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Vaxcyte by 47.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock worth $148,075,000 after purchasing an additional 419,600 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Vaxcyte in the third quarter worth about $41,114,000. Finally, Maverick Capital Ltd. increased its holdings in Vaxcyte by 93.7% in the second quarter. Maverick Capital Ltd. now owns 687,908 shares of the company’s stock valued at $51,944,000 after buying an additional 332,777 shares during the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on PCVX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, The Goldman Sachs Group initiated coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte presently has a consensus rating of “Buy” and a consensus price target of $145.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.